Amplatzer Ventricular Septal Occluders

The Importance of Treating Patients with VSD

Amplatzer VSD Occluders

The Amplatzer™ Muscular VSD Occluder is indicated for use in patients with a complex ventricular septal defect (VSD) of significant size to warrant closure—large volume left-to-right shunt, pulmonary hypertension, and/or clinical symptoms of congestive heart failure—in patients who are considered to be at high risk for standard transatrial or transarterial surgical closure based on anatomical conditions and/or based on overall medical condition.

  • Benefits, Ease of Transcatheter Closure OF VSDS
    Mary Minette, et al.1

    “The benefits of avoiding [cardiopulmonary] bypass are intuitive, and the relative ease of placement makes this procedure ultimately attractive.”


When Closure Should be Performed

Both transcatheter and surgical closure are options for patients with moderate to large VSDs. In particular, physicians should perform VSD closure when the patient has:

  • Left ventricular (LV) volume overload and hemodynamically significant shunts, with pulmonary-to-systemic blood flow ratio (Qp/Qs) of 1.5 or higher*
  • Worsening aortic regurgitation (AR) caused by perimembranous VSD   

In patients whose VSD is not repaired, there is an increased risk of infective endocarditis (IE), usually involving the tricuspid and pulmonary valves.

*Assuming that pulmonary artery (PA) systolic pressure is less than 50% systemic and pulmonary vascular resistance is less than one-third systemic.

Treatment for Post-MI Muscular VSD Is Critical

A post-myocardial infarction muscular VSD is a life-threatening complication that often leads to cardiogenic shock.3 Notably, medical management alone is associated with a grim prognosis of a 94% mortality rate at 30 days.4

The Amplatzer™ Post-infarct Muscular VSD Occluder is a percutaneous transcatheter occlusion device intended for closure of post-myocardial infarction muscular VSD.5

  • Amplatzer Was “Just the Right Device” for VSD

    Due to his VSD Jozef developed endocarditis, which in turn led to heart failure and kidney failure. After receiving an Amplatzer VSD Occluder, Jozef, astonished at his symptom improvement, noted “I feel joy deep inside me—inside my heart.”


To learn more about ventricular septal defects and read frequently asked questions by patients, please visit

MAT-2008370 v1.0 | Item approved for Global OUS use only.

  1. Minette MS, Sahn DJ. Ventricular septal defects. Circulation. 2006;114:2190-2197.
  2. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;73(12):e81-e192. doi: 10.1161/CIR.0000000000000603.
  3. Schlotter F, de Waha S, Eitel I, et al. Interventional post-myocardial infarction ventricular septal defect closure: a systematic review of current evidence. EuroIntervention. 2016;12:94-102.
  4. Crenshaw BS, Granger CB , Birnbaum Y, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. Circulation. 2000;101(1):27-32.
  5. AMPLATZER™ Muscular VSD Occluder and P.I. Muscular VSD Occluder Instructions for Use ARTMT600034253 B 2019-02.

Sign up

Receive updates from Abbott Structural Heart


Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.


You are now leaving Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.